What 8 Analyst Ratings Have To Say About Vir Biotechnology
Portfolio Pulse from Benzinga Insights
In the last quarter, Vir Biotechnology (NASDAQ:VIR) received 5 bullish, 1 somewhat bullish, and 2 indifferent analyst ratings. The company's average 12-month price target is $42.12, a 24.79% decrease from the previous average of $56.00.
September 08, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Vir Biotechnology received mostly positive analyst ratings in the last quarter, but the average 12-month price target decreased by 24.79%.
While the majority of analyst ratings for Vir Biotechnology were positive, the decrease in the average 12-month price target could indicate a less optimistic outlook for the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100